AbbVie to buy drug developer Cerevel for $8.7 billion
AbbVie is to buy Cerevel Therapeutics, a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its arthritis drug Humira faces a raft of new competition.
Business
• 07 Dec 23
